4.7 Article

Defeating Alzheimer's disease and other dementias: a priority for European science and society

Journal

LANCET NEUROLOGY
Volume 15, Issue 5, Pages 455-532

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/S1474-4422(16)00062-4

Keywords

-

Funding

  1. AlzProtect
  2. Genoscreen
  3. Hoffmann-La Roche
  4. Servier
  5. Takeda
  6. Acadia
  7. Lundbeck
  8. GlaxoSmithKline
  9. Heptares
  10. Lilly
  11. Orion
  12. Otusaka
  13. Roche
  14. Tau Therapeutics
  15. Nutricia
  16. Eli Lilly
  17. Brain Canada Multi-Investigator Research Initiative
  18. Canadian Institutes of Health Research
  19. US National Institutes of Health
  20. Pacific Alzheimer Research Foundation
  21. TauRx Therapeutics
  22. Alzheimer Society of Canada
  23. Arena Pharmaceuticals
  24. Biogen
  25. General Electric
  26. Hakko Kyowa Kirin Pharmaceuticals
  27. Isis Pharmaceuticals
  28. Swedish Alzheimer Foundation
  29. Gun and Bertil Stohne Foundation
  30. Karolinska Institutet
  31. King Gustaf V and Queen Victoria's Foundation of Freemasons
  32. Swedish Brain Power
  33. Swedish Research Council
  34. Novartis
  35. Piramal
  36. Schwabe
  37. Pfizer Centers for Therapeutic Innovation
  38. GE Healthcare
  39. Stichting VUMC Fonds
  40. Janssen Research Foundation
  41. Takeda Pharmaceuticals
  42. Baxter
  43. Forum
  44. Merck
  45. US National Institute on Aging
  46. University of Southern California
  47. AC Immune
  48. vTv Therapeutics
  49. Boehringer Ingelheim
  50. Sanofi
  51. Brain Biomarker Solutions
  52. GU-Venture-based platform company at the University of Gothenburg, Sweden
  53. National Institute for Health Research [NF-SI-0611-10084] Funding Source: researchfish

Ask authors/readers for more resources

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available